1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
679CC33FA6EE19F3365257D880046696D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-excellence-showing-value-of-medical-affairs-function?opendocument
18
19opendocument
2034.236.145.124
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Affairs Excellence

Medical Affairs Excellence: Showing the Value of the Medical Affairs Function

ID: 5333


Features:

14 Info Graphics

18 Data Graphics

400+ Metrics


Pages/Slides: 38


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Medical Affairs Excellence: Showing the Value of the Medical Affairs Function"

STUDY OVERVIEW

The changing healthcare landscape has pushed the Medical Affairs function into an increasingly important role involving clinical development, regulatory compliance and market education. While the importance of the medical function is recognized, Medical Affairs leaders often find it challenging to identify strong performance metrics to demonstrate the value of their function to key internal stakeholders.

Best Practices, LLC undertook this study to help organizations find better ways to create and communicate strong Medical Affairs performance metrics to demonstrate value to leadership. Leading insights and metrics in the document will help Medical Affairs leaders create a blueprint for showing the value of the function to internal leadership.

KEY TOPICS

  • Study Overview
  • Key Recommendations
  • Key Findings & Insights
  • Metrics for MA Activities to Show the Success to Stakeholders
  • Communicating the Value of Medical Affairs

SAMPLE KEY METRICS
  • Effectiveness of Overall Medical Affairs Metrics in communicating the value and success of the organization to stakeholders
  • Effectiveness of Scientific Publications Metrics, Medical Education Metrics, Thought Leader Management, MSL Metrics and Medical/Clinical Operations Metrics in communicating the value and success of organization to stakeholders
  • Relative importance of Medical Affairs activities to senior leadership
  • Methods/Channels used to communicate the value of Medical Affairs activities to stakeholders

SAMPLE KEY FINDINGS
  • Scientific Publication Metrics: 60% of the benchmark class thinks that % publications in top-tier journals is a highly effective metric. In addition, more than 40% of the participants agree that % papers and publications accepted is highly effective to evaluate scientific publication performance.
  • Segments: We observed an important difference in perceived effectiveness of % publications in top-tier journals between MCS and the rest of the benchmark class. While one thirds of MCS doesn’t find this metric effective, rest of the benchmark class thinks that % publications in top-tier journals is highly effective or effective to measure their publication performance.

METHODOLOGY

Best Practices, LLC engaged 29 executives from 26 leading life sciences companies. Segmentation analysis was key to examining trends and effective practices. 11 participants make up the Large Companies Segment, while the Mid-Size Companies Segment consists of 10 participants and Small Companies Segment consists of 8 participants.


Industries Profiled:
Pharmaceutical; Biotech; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Manufacturing; Consumer Products; Diagnostic; Medical Device


Companies Profiled:
Astellas; UCB Pharma; Onyx Pharmaceuticals; Upsher-Smith; Medunik Canada; ViiV Healthcare; Purdue Pharma; Xenoport; Lilly; Sanofi; Insys Therapeutics; Theravance; Lundbeck; Bayer; Merck; Ipsen; Merz Pharma; Amgen; Janssen; Baxter BioScience; Jazz Pharmaceuticals; AstraZeneca; Biogen Idec; Axon Pharma; Boehringer Ingelheim; Eisai


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.